Title
Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago
A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago
Phase
Phase 3Lead Sponsor
Eurofarma Laboratorios S.A.Study Type
InterventionalStatus
WithdrawnIndication/Condition
Acute LumbagoIntervention/Treatment
cyclobenzaprine meloxicam ...Study Participants
0The purpose of this study is to assess the efficacy end tolerability of a new drug containing the combination meloxicam and cyclobenzaprine (7,5/10mg) and the same components alone in the treatment of acute lumbago.
To assess the efficacy and tolerability of a new drug containing the combination meloxicam and cyclobenzaprine in the treatment of acute lumbago, compared to the same components alone.
Some eligibility criteria:
Have a normal X-ray of the lumbar spine for the age; Have a baseline score in the VAS higher than or equal to 40 mm
two oral tablet a day during approximately 07 days
two oral capsules a day during approximately 07 days
two oral tablet a day during approximately 07 days
Inclusion Criteria: Sign, initial and date the Informed Consent Form (ICF); Be between 18 and 75 years old; Have acute lumbago with onset in less than 72 hours; Have a normal X-ray; Have a baseline score in the VAS higher than or equal to 40 mm; Exclusion Criteria: Use of triptans; Use of monoamine oxidase inhibitors; Use of NSAIDs within the last week; Previous use of narcotics; Have any rheumatologic disease; Conditions of chronic pain; Have any significant chronic comorbidity; Previous history of gastrointestinal bleed or ulcers; History of allergy to any of the components of study medications; Recent history of a myocardial infarction, cardiac arrhythmia, cardiac conduction block or change, or congestive heart failure; Female patients who are pregnant or breastfeeding or who wish to become pregnant or who deny using safe contraceptive methods during the study will not be enrolled in the study; Have participated in another clinical trial within the last 12 months.